Final analysis of the phase 3 EMERALD trial in HER2-positive advanced breast cancer: first-line eribulin vs taxane, both with trastuzumab plus pertuzumab, showed no significant OS difference (median 78.5 months vs not reached; HR 1.25, P=0.19).
RCT
Saji et al. Eribulin versus taxane as first-line chemotherapy combined with dual HER2 blockade in patients with HER2-positive locally advanced or metastatic breast cancer: final survival outcomes of the JBCRG-M06/EMERALD study